Abstrait

Study on detection of platelet membrane glycoprotein CD62p in patient with atrial fibrillation after radiofrequency ablation treatment

Feifei Tian, Yongjun Mao, Shanglang Cai, Xiaofei Sun

Objective: As a type of arrhythmia, Atrial Fibrillation (AF) seriously affects human health. Although Radiofrequency Catheter Ablation (RFCA) has been proved to be a safe and effective method for the treatment of AF, thromboembolism caused by this treatment limited its application. Our study aimed to investigate the effects of calcium channel blocker amlodipine on thrombosis-related factors after RFCA.

Methods: A total of 68 patients with AF underwent RFCA were selected from Jining No.1 People's Hospital from September 2015 to December 2016. Patients were randomly divided into groups A and B. Patients in group A received RFCA only, while patients in group B were treated with amlodipine for 3 consecutive days before RFCA. Elbow venous blood was extracted from each patient before intravenous catheterization, after electrophysiological examination and before RFCA, just after RFCA, 24 h after RFCA and 48 h after RFCA. Levels of CD62P, Thromboxane B2 (TXb2), Interleukin 6 (IL6), D-Dimer and protein C in plasma were detected by Enzyme-Linked Immunosorbent Assay (ELISA).

Results: Compared with preoperative levels, levels of CD62P, TXb2, IL6, D-Dimer and protein C in plasma of group A were significantly increased after RFCA (p<0.05), and then decreased. But no significantly differences were found between preoperative levels and levels at 48 h after operation. No significant differences in levels of CD62P, TXb2, IL6, D-Dimer and protein C in plasma were found between different time points in group B.

Conclusion: RFCA in the treatment of atrial fibrillation can increase the risk of thrombosis, while preoperative treatment with amlodipine can reduce the risk.